louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06395896: The Effect of Breast Cancer Prevention Journey Program
Official title: The Effect of Breast Cancer Prevention Journey Program on Women's Health Beliefs Towards Breast Cancer: Quasi Experimental Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer Female
Keywords: Breast Neoplasms
Health Belief Model
Mammography
Lead sponsor: Lokman Hekim Üniversitesi
Sponsor class: OTHER_GOV
Collaborators: name: The Scientific and Technological Research Council of Turkey
First posted: 2024-05-02
Enrollment: 70
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: There are two groups: experimental group and control group.
Primary purpose: PREVENTION

Brief summary: The aim of this quasi-experimental study is to determine the effect of the "Breast Cancer Prevention Journey Program" on health beliefs about breast cancer in women over 40 years of age who have never had a mammogram before. The research aims to answer the following basic questions:

-Do women who participated in the "Breast Cancer Prevention Journey Program" have different health beliefs about breast cancer than women who did not participate in the program? The researchers will compare the program with routine care to see if the "Breast Cancer Prevention Journey Program" works. The study will be conducted in a quasi-experimental design with a pre-test post-test control group.

Participants in the experimental group will first participate in the "The fight against breast cancer" training structured according to the Health Belief Model. One week after the training, the participants in the experimental group will be taken to mammography screening with free shuttles.

Participants in the control group will not receive any additional intervention. This group will only receive routine intervention within the scope of the breast cancer screening program conducted by the Ministry of Health.


Eligibility criteria: Inclusion Criteria:

* Being a woman between the ages of 40-69
* Having never had a mammogram before

Exclusion Criteria:

* Being diagnosed with breast cancer
* Having had a breast operation

Primary outcomes:
measure: Champion's Health Belief Model Scale in Breast Cancer Screening
timeFrame: two week
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Lokman Hekim Üniversitesi
state: Çankaya
Study officials:
affiliation: Lokman Hekim Universty
name: Nurbanu Odacı, Master
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00952796: A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections
Official title: A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Intra-abdominal Infection
Keywords: intra-abdominal infection
moxifloxacin
ampicillin/sulbactam
Lead sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor class: OTHER
First posted: 2009-08-06
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: On the basis of monotherapy for intra-abdominal infection, the investigators are conducting this study to identify the difference of drug efficacy between ampicillin/sulbactam and moxifloxacin.


Eligibility criteria: Inclusion Criteria:

* patients diagnosed of complicated intra-abdominal infection need surgical treatment

Exclusion Criteria:

* patients diagnosed of intra-abdominal infection receive non-operative management
* patients with known allergic history of fluoroquinolone
* Severe, life threatening disease with a life expectancy of \< 48 h or APS and APACHE scores of \> 35

Primary outcomes:
measure: clinical response at test-of-cure visit
timeFrame: test of cure: 10-14 days after initial treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Hospital, Department of Emergency Medicine/Surgery
Study officials:
References:
Clinical trial NCT01331096: Tele-Anesthesia - Trans-Continental Anesthesia Compared to Standard Practice
Official title: Tele-Anesthesia - Trans-Continental Anesthesia Compared to Standard Practice
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Thyroid Gland Resection
Keywords: thyroid gland resection surgery
total intravenous anesthesia
Lead sponsor: Azienda Ospedaliero, Universitaria Pisana
Sponsor class: OTHER
Collaborators: name: McGill University Health Centre/Research Institute of the McGill University Health Centre
First posted: 2011-04-07
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing elective thyroid gland surgery

Brief summary: Patients in Pisa will undergo thyroid gland surgery. In the protocol group anesthesia will be performed using an automated anesthesia delivery system; preoperative and intra-operative assessment of patients will be performed via video-conferencing from Montreal, which will also monitor and control anesthesia delivery via distant Internet connection - as supervision of functioning of the automated anesthesia delivery system. In the control group anesthesia will be performed in a standard fashion with manual control of the syringe pumps infusing anesthetics drugs.

The hypothesis is that Tele-anesthesia, considered as preoperative assessment and anesthetic control of an automated anesthesia delivery system is feasible and reliable via standard means of internet communication (distant control via virtual network) and performed as well or even better than manual control of the anesthetic drugs infusion.


Eligibility criteria: Inclusion Criteria:

* Elective patients
* Patient scheduled for surgery under spinal anesthesia
* Patients aged 18 to 85 years

Exclusion Criteria:

* Unable to provide informed consent
* Comatose patients
* Patients with dementia
* Allergy to Propofol

Primary outcomes:
measure: Performance of closed-loop system for propofol administration, controlled remotely, compared with the performance of propofol manually administered to maintain in both case the level of hypnosis close to the BIS target.
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Pisa
country: Italy
facility: Azienda Ospedaliero-Universitaria Pisana
state: PI
Study officials:
References:
citation: Hemmerling TM, Arbeid E, Wehbe M, Cyr S, Giunta F, Zaouter C. Transcontinental anaesthesia: a pilot study. Br J Anaesth. 2013 May;110(5):758-63. doi: 10.1093/bja/aes498. Epub 2013 Mar 10.
Clinical trial NCT04317196: Association of Copy Number Variations in the SMN Genes With Acute Kidney Injury After Heart Surgery
Official title: Molecular Epidemiology Study of the Association of Copy Number Variations in the SMN Genes With Acute Kidney Injury After Heart Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Kidney Injury
Lead sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2020-03-23
Enrollment: 1206
Sex: ALL
Minimum age (years): 1
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients from Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Brief summary: This prospective cohort study aims to explore the susceptibility to acute kidney injury after heart surgery in SMN1+/- genotype population. This study also aims to analysis the effect of SMN1+/- genotype on postoperative AKI and the development of chronic kidney disease, as well as dose-compensating effect of different copy number of SMN2 gene on SMN1 +/- genotype.

Detailed description: This prospective cohort study aims to explore the susceptibility to acute kidney injury after heart surgery in SMN1+/- genotype population. Real-time PCR is used to detect copy number variations in the peripheral blood SMN gene on 1206 patients with heart surgery. This study also aims to analysis the effect of SMN1+/- genotype on postoperative AKI and the development of chronic kidney disease, as well as dose-compensating effect of different copy number of SMN2 gene on SMN1 +/- genotype.

Eligibility criteria: Inclusion Criteria:

* Age: Children (1 month -17 years old) and adults (18-80 years old);
* Sex: All;
* Those who will receive selective cardiac surgery with cardiopulmonary bypass;
* Those who signed the informed consent.

Exclusion Criteria:

* Those with glomerular filtration rate: eGFR\<15ml/min/1.73m2, and those who have received the renal replacement therapy before surgery;
* Those who have received nephrectomy and kidney transplantation;
* Those who have suffered from AKI before;
* Those with incomplete medical history or clinical data.

Primary outcomes:
measure: Number of participants with occurrence of acute kidney injury (AKI) after cardiac surgery
timeFrame: 48 hours
Secondary outcomes:
measure: Number of participants with occurrence of acute kidney disease (AKD) after cardiac surgery
timeFrame: 3 months
measure: Glomerular Filtration Rate(GFR)
timeFrame: 90 days
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Study officials:
References:
Clinical trial NCT01180296: Oral Progesterone for Prevention of Preterm Birth
Official title: Prevention of Recurrent Preterm Birth With Micronized Progesterone
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Preterm Birth
Keywords: Preterm birth, prevention, progesterone, oral
Lead sponsor: Fetal Medicine Foundation
Sponsor class: OTHER
First posted: 2010-08-12
Enrollment: 36
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To evaluate whether daily oral micronized progesterone is effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal serum progesterone levels.

Detailed description: To evaluate whether 400 mg daily oral micronized progesterone from 16 to 34 weeks' is effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal serum progesterone levels.

Eligibility criteria: Inclusion Criteria:

* pregnant women less than 20 weeks' gestation who had at least one prior spontaneous preterm birth of a liveborn baby between 20 \& 0/7 weeks' and 36 \& 6/7 weeks' gestation.

Exclusion Criteria:

* multiple gestations, the presence of major fetal anomalies, progesterone use in the current pregnancy (ongoing or past), the presence of a cervical cerclage, and the presence of a placenta previa.

Primary outcomes:
measure: Rate of Recurrent Preterm Birth
timeFrame: Prior to 37 weeks' gestation
Secondary outcomes:
measure: Secondary Outcomes
timeFrame: Mean +/- Std Dev gestational age of 25.9/-2.4 weeks in Progesterone group, and 28.4 +/-4.7 weeks in placebo group
Other outcomes:
Locations:
city: Dayton
country: United States
facility: Miami Valley HospitaL
state: Ohio
Study officials:
affiliation: Fetal Medicine Foundation/USA
name: David S McKenna, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00792896: Intervention Toward Truth-Telling and Advanced Directives in the Patient With Advanced or Metastatic Disease
Official title: A Longitudinal Study That Assessed the Effectiveness of Intervention Toward
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Advanced Cancer
Metastatic Cancer
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: National Science and Technology Council, Taiwan
First posted: 2008-11-18
Enrollment: 150
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Family usually had a lot of burden to tell the truth to patients. The purpose of this study is to assess the effect of education materials and family conference for advanced cancer patients and family.


Eligibility criteria: Inclusion Criteria:

* advanced or metastatic cancer patients
* more than 20 years old
* clear consciousness and be able to communicate

Exclusion Criteria:

* refuse to know the statement of himself/herself disease

Primary outcomes:
measure: Questionnaires
timeFrame: before and 1 week after the intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
References:
Clinical trial NCT01978496: Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine
Official title: A Multicenter Double-blind, Randomized Placebo Controlled, Parallel Group, Study of the Efficacy and Safety of Oral Eletriptan in Subjects With Acute Migraine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Migraine With or Without Aura
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2013-11-07
Enrollment: 1334
Sex: ALL
Minimum age (years): 18
Maximum age (years): 78
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To confirm the efficacy of three dose levels of oral eletriptan relative to placebo in relieving symptoms of acute migraine and to further explore the dose response relationship of eletriptan.


Eligibility criteria: Inclusion Criteria:

* History of at least one typical attack of migraine with or without aura every 6 weeks, as defined by the International Headache Society (IHS) criteria.
* Capable of taking study medication as outpatients and recording its effects.

Exclusion Criteria:

* Pregnant or breast-feeding women
* Migraine subjects who also suffered from concomitant frequent (non-migraine) headache, defined as more than six headaches per month on average
* Migraine attacks that were thought to be atypical and had consistently failed to respond to medical therapy.

Primary outcomes:
measure: Headache responder rate at two hours after the first dose for the first attack.
timeFrame: 2 hours
Secondary outcomes:
measure: Pain free responder rate at two hours after the first dose for the first attack.
timeFrame: 2 hours
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT05639296: Expert Learning in Musculoskeletal Ultrasound
Official title: Expert Learning in Musculoskeletal Ultrasound - the Effect of Discovery Learning
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Musculoskeletal Diseases
Keywords: Medical education
Ultrasound
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2022-12-06
Enrollment: 38
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Physicians with a Rheumatology background. All experts in the field of MSUS.

Brief summary: Musculoskeletal ultrasound (MSUS) is a complex procedure and requires lifelong theoretical and practical training to ensure continued professional development.

Currently, the teaching approach for experts in MSUS is theoretical preparation first and then hands-on training, the "Tell-Then-Do" approach. The existing literature on optimizing training for experts is sparse, and it is unknown if the training intervention Discovery Learning could be a more effective teaching method for this group of learners.


Eligibility criteria: Inclusion Criteria:

* Experts in MSUS, defined as physicians who have performed more than 1000 MSUS examinations

Exclusion Criteria:

* Physicians who have not performed 1000 MSUS examinations.

Primary outcomes:
measure: How do experts in MSUS approach a new and unfamiliar MSUS task?
timeFrame: January 2023
Secondary outcomes:
measure: How do the experts respond to DL?
timeFrame: January 2023
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Barcelona University
Study officials:
affiliation: COPECARE (Copenhagen Center for Arthritis Research) Rigshospitalet, Glostrup
name: Stine Maya Dreier Carstensen, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Brydges R, Fiume A, Grierson L. Mastery versus invention learning: impacts on future learning of simulated procedural skills. Adv Health Sci Educ Theory Pract. 2022 May;27(2):441-456. doi: 10.1007/s10459-022-10094-x. Epub 2022 Mar 23.
citation: Steenhof N, Woods NN, Van Gerven PWM, Mylopoulos M. Productive failure as an instructional approach to promote future learning. Adv Health Sci Educ Theory Pract. 2019 Oct;24(4):739-749. doi: 10.1007/s10459-019-09895-4. Epub 2019 May 14.
citation: Terslev L, Hammer HB, Torp-Pedersen S, Szkudlarek M, Iagnocco A, D'Agostino MA, Schmidt WA, Uson J, Bruyn GA, Filippucci E, Moller I, Balint P, Wakefield R, Naredo E. EFSUMB minimum training requirements for rheumatologists performing musculoskeletal ultrasound. Ultraschall Med. 2013 Oct;34(5):475-7. doi: 10.1055/s-0033-1335143. Epub 2013 May 21.
Clinical trial NCT01039896: A Drug Interaction Study of SLM0807 and HKB0701 in Healthy Subjects
Official title: An Open-label, Randomized, Crossover Study to Evaluate the Safety and Pharmacokinetics After Multiple Administration of SLM0807 Alone and Multiple Co-administration of HKB0701/SLM0807 in Korean Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetes Mellitus
Lead sponsor: HK inno.N Corporation
Sponsor class: INDUSTRY
First posted: 2009-12-25
Enrollment: 24
Sex: ALL
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of this study is to assess whether HKB0701 alters pharmacokinetics of SLM0807.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers who are in age range of 20-50years and the weight range is not exceed ±20% of ideal weight. Ideal weight = \[height -100\]\*0.9
* Subjects with no history of any significant chronic disease
* Judged to be in good health on the basis of their vital sign, ECG, physical exam and routine laboratory data
* Available for the entire study period
* Willing to adhere to protocol requirements and sign a informed consent form.

Exclusion Criteria:

* Subjects who have taken any drugs to induce or inhibit hepatic enzyme activity within 30days prior to drug administration
* Subjects who have symptom of an acute illness within 4 weeks prior to drug administration
* Subjects with a history of clinically significant allergies including drug allergies
* Subjects whose clinical laboratory test values are outside the accepted normal range(Especially,AST or ALT \>1.25 times to normal range or total bilirubin \> 1.5times to normal range)
* Subjects with a history of drug, caffeine or alcohol abuse (caffeine drink \>5cups /day, alcohol \>30g/day)
* Heavy smoker ( \>10cigarettes/day)
* Subjects who have had a diet known to interfere with the absorption, distribution, metabolism or excretion of drugs (especially, consumption of grapefruit juice)
* Subjects who have donated plasma within 60days prior to drug administration
* Subjects who have participated in a clinical study within 90days prior to drug administration
* Subjects who have received any drugs that might confound the results of the trial in the opinion of principal investigator (cimetidine within 7days prior to drug administration)
* Female subjects who are pregnant, breastfeeding or not using medically acceptable birth control

Primary outcomes:
measure: Css,max and AUCinf
timeFrame: up to 24hrs
Secondary outcomes:
measure: AUCtau, AUCt, Tmax
timeFrame: up to 24hrs
Other outcomes:
Locations:
Study officials:
affiliation: Inje University
name: Jae Gook Shin, MD, ph D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kim HS, Oh M, Kim EJ, Song GS, Ghim JL, Shon JH, Kim DH, Shin JG. Effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects. Int J Clin Pharmacol Ther. 2014 Nov;52(11):1005-11. doi: 10.5414/CP202160.
Clinical trial NCT01819896: Safety of Smartphones Among Patients With Cardiac Implantable Electronic Devices
Official title: Safety of Smartphones Among Patients With Cardiac Implantable Electronic Devices
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Recipients of Implantable Pacemakers or Defibrillators
Lead sponsor: Deutsches Herzzentrum Muenchen
Sponsor class: OTHER
First posted: 2013-03-28
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Recipients of implantable pacemakers or defibrillators

Brief summary: Over the past year smartphones have developed from a niche product to a commoditized product and are now squeezing classic mobile phones out of market. According to a survey a quarter of the German population is making use of a smartphone at present.

An interference between smartphones and the functionality of pacemakers or implantable defibrillators is rather unlikely but cannot entirely be excluded. A systematic study regarding a possible interference between smartphones and modern pacemaker- and ICD-system with a better shielding against external influence has not taken place so far. In this study the investigators intend to investigate any interference between different smartphones produced by different manufacturers and diverse cardiovascular implanted electronic devices.


Eligibility criteria: Inclusion Criteria:

* Presence of an implantable pacemaker or defibrillator

Exclusion Criteria:

* Lead malfunction which can not reprogrammed
* Battery depletion

Primary outcomes:
measure: Interference of smartphones with cardiac implantable electronic devices
timeFrame: acute study (no follow-up)
Secondary outcomes:
Other outcomes:
Locations:
city: München
country: Germany
facility: Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen
state: Bayern
Study officials:
References: